Results 31 to 40 of about 2,605,313 (261)

Association of intraoperative gross hematuria with acute kidney injury after cytoreductive surgery

Pleura and Peritoneum, 2022
–Early detection and treatment of postoperative acute kidney injury is essential.–How to prevent acute kidney injury after cytoreductive surgery is unclear.–Intraoperative hematuria is related to postoperative acute kidney injury.–Hematuria is easily ...
Mitani Yumi, Arai Yohei, Tomohiro Mitani, Gohda Yoshimasa, Yano Hideaki, Kondo Isao, Sakamoto Emi, Katagiri Daisuke, Hinoshita Fumihiko   +8 more
doaj   +1 more source

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio, Biacchi, Daniele, Cardi, Maurizio, DI GIORGIO, Angelo, Mingarelli, Valentina, Musio, Daniela, Sammartino, Paolo, Sibio, Simone, Sollazzo, BIANCA MARIA   +8 more
core   +2 more sources

Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]

, 2019
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica, Cardi, Maurizio, D'Agostino, Claudia, Fonsi, Giovanni Battista, Francesco Di Marzo,, Francesco, Lefoche, LA TORRE, Giuseppe, Sammartino, Paolo, Sibio, Simone   +8 more
core   +1 more source

Evaluation of the relationship between lactacidemia and postoperative complications after surgery for peritoneal carcinomatosis [PDF]

Korean Journal of Anesthesiology, 2021
Background Cytoreductive surgery was developed as a treatment for peritoneal carcinomatosis. However, this surgery is associated with important complications.
Marta Soriano Hervás, Rosa Játiva-Porcar, Daniel Robles-Hernández, Anna Serra Rubert, Blanca Segarra, Cristina Oliva, Javier Escrig, José Antonio Llueca   +7 more
doaj   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

Treatment options for PNET liver metastases. a systematic review [PDF]

, 2018
Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo, Crovetto, Anna, Debs, Tarek, Mangogna, Livia Maria, Moschetta, Giovanni, Nigri, Giuseppe, Persechino, Raffaello, Petrucciani, Niccolò, Ramacciato, Giovanni   +8 more
core   +1 more source

Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study

World Journal of Surgical Oncology, 2019
Background Standard treatment for colorectal peritoneal carcinomatosis typically involves cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), and if possible, postoperative adjuvant chemotherapy. However, a substantial percentage of
M. Leimkühler, P. H. J. Hemmer, A. K. L. Reyners, D. J. A. de Groot, R. J. van Ginkel, L. B. Been, G. H. de Bock, B. L. van Leeuwen   +7 more
doaj   +1 more source

Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer [PDF]

, 2019
Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics ...
Ceelen, Wim, De Clercq, Kaat, De Wever, Olivier, Descamps, Benedicte, Hoorens, Anne, Vermeulen, An, Vervaet, Chris, Xie, Feifan   +7 more
core   +2 more sources

Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients

World Journal of Surgical Oncology, 2022
Background Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods A total of 52 female MPM patients treated in 2012–2017
Jianting Ma, Shengzhi Zhang
doaj   +1 more source

Cerebral edema in a patient following cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemoperfusion

World Journal of Surgical Oncology, 2006
Background Cytoreductive surgery and intraoperative, intraperitoneal hyperthermic chemoperfusion (HIPEC) is increasingly used to treat peritoneal surface metastases.
Stemmerman Grant, Tobias Jonathan, Nair Rajalakshmi L, Lowy Andrew M   +3 more
doaj   +1 more source